Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference9 articles.
1. Guy H, Walder L, Fisher M. Cost-effectiveness of niraparib versus routine surveillance, olaparib and rucaparib for the maintenance treatment of patients with ovarian cancer in the United States. Pharmacoeconomics. 2019;37(3):391–405.
2. Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17(11):1579–89.
3. Institute for Clinical and Economic Review. Poly ADP-ribose polymerase (PARP) inhibitors for ovarian cancer: effectiveness and value. 2017.
https://icer-review.org/wp-content/uploads/2017/02/MWCEPAC_OVARIAN_FINAL_EVIDENCE_REPORT_10112017-1.pdf
. Accessed 15 Feb 2019.
4. Sackeyfio A, Nussey F, Friedlander M, Pujade-Lauraine EJGO. Comparative efficacy and tolerability of the PARP inhibitors, olaparib 300 mg tablets BID, niraparib 300 mg capsules QD and rucaparib 600 mg tablets BID as maintenance treatment in BRCA-mutated (BRCAm) platinum-sensitive relapsed ovarian. Gynecol Oncol. 2018;149:43–4.
5. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–92.